Derivatives of dehydrodidemnin B

Details Derivatives of dehydrodidemnin B Derivatives of dehydrodidemnin B

2005-05-23

2008-03-25

Marschel, Ardin H. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S008100, C514S009100

Reexamination Certificate

active

07348311

ABSTRACT:
Dehydrodidemnin B with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivatives

REFERENCES:
patent: 4493796 (1985-01-01), Rinehart, Jr.
patent: 4670262 (1987-06-01), Battelli et al.
patent: 4952399 (1990-08-01), Lewenstein et al.
patent: 5294603 (1994-03-01), Rinehart
patent: 5462726 (1995-10-01), Lodge
patent: 5834586 (1998-11-01), Rinehart et al.
patent: 6034058 (2000-03-01), Rinehart et al.
patent: 6153731 (2000-11-01), Rinehart et al.
patent: 6156724 (2000-12-01), Rinehart et al.
patent: 6710029 (2004-03-01), Rinehart et al.
patent: 0 048 149 (1982-03-01), None
patent: 0 393 883 (1990-10-01), None
patent: 2 102 322 (1997-07-01), None
patent: WO 91/04985 (1991-04-01), None
patent: WO 93/00362 (1993-01-01), None
patent: WO 98/17275 (1998-04-01), None
patent: WO 98/17302 (1998-04-01), None
patent: WO 99/42125 (1999-08-01), None
patent: WO 01/35974 (2001-05-01), None
patent: WO 01/76616 (2001-10-01), None
patent: WO 02/02596 (2002-01-01), None
patent: WO 02/30441 (2002-04-01), None
Goodman &Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), Calabresi et al., Section X, Chemotherapy of Neoplastic Diseases, pp. 1225-1229.
Osol A. [Editor] “Chapter 27: Structure-Activity Relationship and Drug Design”. Remington's Pharmaceutical Sciences (Sixteenth Edition), 1980. pp. 420-435.
Jiang et al. “Antitumor Activity of Didemnin B in the Human Tumor Stem Cell Assay”. Cancer Chemotherapy and Pharmacology. 1983, 11:1-4.
Jouin et al. “Antineoplastic Activiyt of Didemnin Congeners: Nordidemnin and Modified Chain Analogues”. Journal of Medicinal Chemistry. 1991, 34:486-491.
Jacob L. “General Pharmacologic Principles”. Pharmacology (Fourth Edition). Williams and Wilkins Company, 1996. pp. 1-13.
Ady-Vago, N. et al., “L-Carnitine as a Protector Against Aplidine Induced Skeletal Muscle Toxicity”,Proceedings of the American Association for Cancer Research, vol. 42, pp. 545 (Mar. 2001).
Bergeron, Raymond J. et al., “Antineoplastic and Antiherpetic Activity of Spermidine Catecholamide Iron Chelators,”Biochemical and Biophysical Research Communications, vol. 121, No. 3, pp. 848-854 (1984).
Chapa, A.M. et al., “Influence of Intravenous L-Carnitine Administration In Sheep Preceding an Oral Urea Drench,”Journal of Animal Science, vol. 76, No. 11, pp. 2930-2937 (1998).
Depenbrock, H. et al., “In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells,”British Journal of Cancer, vol. 78, No. 6, pp. 739-744 (1998).
Erba, E. et al., “Cell cycle phases perturbations induced by new natural marine compounds,”Annals of Oncology, vol. 7, Supplement 1, #283, pp. 82 (1996).
Faircloth, G. et al., “Aplidine (APL) is a novel marine-derived depsipeptide with in vivo antitumor activity,”Proceedings of the American Association for Cancer Research, vol. 39, #1551, pp. 227 (1998).
Faircloth, G. et al., “Dehydrodidemnin B (DDB) a new marine derived anti-cancer agent (MDA) with activity against experimental tumor models” and “Biological activity of thiocoraline. A new depsipeptide from a marine micromonospora,”Annals of Oncology, vol. 7, Supplement 1, #111 and #112, pp. 34 (1996).
Faircloth, G. et al., “Preclinical characterization of Aplidine (APD), a new marine anticancer depsipeptice (MADEP),”Proceedings of the American Association for Cancer Research, vol. 38, #692, pp. 103 (1997).
Faircloth, G. et al., “Preclinical development of aplidine, a novel marine-derived agent with potent antitumor activity,”Annals of Oncology, vol. 9, Supplement 2, #129, pp. 34 (1998).
Faircloth, G. et al., “Schedule-dependency of aplidine, a marine depsipeptide with antitumor activity,”Proceedings of the American Association for Cancer Research, vol. 40, #2612, pp. 394-395 (1999).
Geldof, Albert A. et al., “Cytotoxicity and neurocytotoxicity of a new marine anticancer agents evaluated using in vitro assays,”Cancer Chemother, Pharmacol., vol. 44, pp. 312-318 (1999).
Genin, Michael J. et al., “Synthesis and Crystal Structure of a Peptidomimetic Containing the (R)-4, 4-Sprio Lactam Type-II β-Turn Mimic,”Journal of Organic Chemistry, vol. 58, No. 8, pp. 2334-2337 (1993).
Gomez-Fabre, P.M. et al., “Polamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B,”Cancer Letters, vol. 113, Nos. 1, 2, pp. 141-144 (1997).
Jou, Gemma et al., “Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution,”Journal of Organic Chemistry, vol. 62, No. 2, pp. 354-366 (1997).
Lobo, C. et al., “Effect of Dehydrodidemnin B on Human Colon Carcinoma Cell Lines,”Anticancer Research, vol. 17, No. 1A, pp. 333-336 (1997).
Mastbergen, S.C. et al., “Cytotoxicity and Neurocytotoxicity of aplidine, a new marine anticancer agent evaluated using in vitro assays,”Annals of Oncology, vol. 9, Supplement 2, #131 (1998).
Nuijen, B. et al., “Pharmaceutical development of anticancer agents derived from marine sources,”Anti-Cancer Drugs, vol. 11, pp. 793-811 (2000).
Raymond, Eric et al., “Preliminary Results of a Phase I and Pharmacokinetic Study of Aplidine Given as a 24-hour Infusion Every 2 Weeks in Patients With Solid Tumors and Non Hodgkin's Lymphomas,”Proceedings of the American Association for Cancer Research, vol. 41, #3886 (2000).
Rinehart, Kenneth L. et al., “Didemnins and Tunichlorin: Novel Natural Products from the Marine Tunicate Trididemnum Solidum,”Journal of Natural Products, vol. 51, No. 1, pp. 1-21 (1988).
Rinehart, Kenneth L., Jr. et a., “Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate,”Science, vol. 212, No. 4497, pp. 933-935 (1981).
Rinehart, Kenneth L., Jr. et al., “Antiviral and antitumor compounds from tunicates,”Federation Proceedings, vol. 42, No. 1, pp. 87-90 (1983).
Sakai, Ryuichi et al., “Structure—Activity Relationships of the Didemnins,”Journal of Medicinal Chemistry, vol. 39, No. 14, pp. 2819-2834 (1996).
Seebach, Dieter et al., “Alkylation of Amino Acids Without Loss of the Optical Activity: Preparation of α-Substituted Proline Derivatives. A Case of Self-Reproduction of Chirality,”Journal of the American Chemical Society, vol. 105, No. 16, pp. 5390-5398 (1983).
Urdiales, Jose L. et al., “Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates,”Cancer Letters, vol. 102, Nos. 1,2, pp. 31-37 (1996).
Vervoort, Helene et al., “Tamandarins A and B: New Cytotoxic Depsipeptides from a Brazilian Ascidian of the Family Didemnidae,”Journal of Organic Chemistry, vol. 65, No. 3, pp. 782-792 (2000).
Montgomery et al.,Fed. Prac., vol. 44, pp. 634 (1987).
Montgomery, D.W. Zukoski, C.F.Transplantation, vol. 40, pp. 49-56 (1985).
Rinehart et al.,J. Am. Chem. Soc., vol. 109, pp. 6846-6848 (1987).
Rinehart, “Didemnin and its Biological Properties,”Escom, pp. 626-631 (1987).
Rinehart, Jr. et al.,Pure and Appl. Chem., vol. 54, pp. 2409-2424 (1982).
K.L. Rinehart, Jr.,J. Am. Chem. Soc., vol. 103, pp. 1857-1859 (1981).

Affiliated with

Also associated with

Rating

Derivatives of dehydrodidemnin B does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of dehydrodidemnin B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of dehydrodidemnin B will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3966265